UROY Stock Analysis: Uranium Royalty | NASDAQ
Uranium | NASDAQ, USA | Market Cap: 1.349m USD | 12M Return: -14.3% | US91703D1000 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 9.87M
Qual. Beats: 1
Rev. Trend: 49.3%
Qual. Beats: 0
Warnings
Tailwinds
Seasonality 6.7 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Uranium Royalty Corp. (UROY) is a small-cap energy company that operates as a uranium and land royalty company, primarily based in Canada but headquartered in Lakewood, Colorado. Its business model focuses on building a portfolio of royalties in the uranium sector, investing in uranium-related companies, and trading physical uranium. The company was incorporated in 2017 and has been publicly traded on NASDAQ since its IPO in April 2021.
The royalty business model allows the company to earn revenue from uranium production without the operational risks and capital costs associated with mining, similar to how precious metals royalty companies (such as Franco-Nevada or Royal Gold) operate in the gold sector. This structure provides exposure to uranium price movements while avoiding direct involvement in extraction, processing, or mine development activities.
- Spot uranium prices surge amid supply constraints and reactor demand
- Royalty revenue grows as portfolio expands with new acquisitions
- US nuclear power policy shifts boost long-term uranium demand
- Small-cap margin volatility rises with physical uranium trading activity
| Net Income: 76.2m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.11 > 0.02 and ΔFCF/TA 9.27 > 1.0 |
| NWC/Revenue: -8.23% < 20% (prev 488.2%; Δ -496.4% < -1%) |
| CFO/TA 0.11 > 3% & CFO 286.9m > Net Income 76.2m |
| Net Debt (671.3m) to EBITDA (93.9m): 7.15 < 3 |
| Current Ratio: 0.88 > 1.5 & < 3 |
| Outstanding Shares: last quarter (157.3m) vs 12m ago 17.66% < -2% |
| Gross Margin: 32.81% > 18% (prev 17.12%; Δ 15.69% > 0.5%) |
| Asset Turnover: 19.73% > 50% (prev 16.36%; Δ 3.37% > 0%) |
| Interest Coverage Ratio: 129.2 > 6 (EBIT TTM 93.5m / Interest Expense TTM 724k) |
| A: -0.01 (Total Current Assets 169.5m - Total Current Liabilities 193.7m) / Total Assets 2.68b |
| B: 0.04 (Retained Earnings 96.4m / Total Assets 2.68b) |
| C: 0.06 (EBIT TTM 93.5m / Avg Total Assets 1.49b) |
| D: 1.17 (Book Value of Equity 1.35b / Total Liabilities 1.15b) |
| Altman-Z'' = 1.71 = BBB |
| DSRI: 3.0 (Receivables 5.89m/22.0k, Revenue 294.2m/48.8m) |
| GMI: 0.52 (GM 17.12% / 32.81%) |
| AQI: 0.13 (AQ_t 0.03 / AQ_t-1 0.20) |
| SGI: 6.03 (Revenue 294.2m / 48.8m) |
| TATA: -0.08 (NI 76.2m - CFO 286.9m) / TA 2.68b) |
| Beneish M = 1.27 (Cap -4..+1) = D |
As of October 25, 2026, the stock is trading at USD 3.43 with a total of 2,811,660 shares traded. Over the past week, the price has changed by -3.11%, over one month by -22.40%, over three months by +10.65% and over the past year by -14.25%.
Current recommended Stop Loss: 3.20 (which is 6.7% or 1.2 ATR below the current price).
Uranium Royalty has received a consensus analysts rating of 4.60. Therefore, it is recommended to buy UROY.
- StrongBuy: 3
- Buy: 2
- Hold: 0
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 4.2 | 23% |
P/E Trailing = 9.3158
P/E Forward = 15.015
P/S = 6.2932
P/B = 1.7712
Revenue TTM = 294.2m USD
EBIT TTM = 93.5m USD
EBITDA TTM = 93.9m USD
Long Term Debt = 535.7m USD (from longTermDebt, last quarter)
Short Term Debt = 80.2m USD (from shortTermDebt, last quarter)
Debt = 832.1m USD (from shortLongTermDebtTotal, last quarter) + Leases 100k
Net Debt = 671.3m USD (calculated: Debt 832.1m - CCE 160.9m)
Enterprise Value = 2.02b USD (1.35b + Debt 832.1m - CCE 160.9m)
Interest Coverage Ratio = 129.2 (Ebit TTM 93.5m / Interest Expense TTM 724k)
EV/FCF = 7.08x (Enterprise Value 2.02b / FCF TTM 285.3m)
FCF Yield = 14.12% (FCF TTM 285.3m / Enterprise Value 2.02b)
FCF Margin = 96.98% (FCF TTM 285.3m / Revenue TTM 294.2m)
Net Margin = 25.91% (Net Income TTM 76.2m / Revenue TTM 294.2m)
Gross Margin = 32.81% ((Revenue TTM 294.2m - Cost of Revenue TTM 197.6m) / Revenue TTM)
Gross Margin QoQ = 33.70% (prev 33.12%)
Tobins Q-Ratio = 0.75 (Enterprise Value 2.02b / Total Assets 2.68b)
Interest Expense / Debt = 0.09% (Interest Expense 724k / Debt 832.1m)
Taxrate = 27.77% (29.3m / 105.5m)
NOPAT = 67.5m (EBIT 93.5m * (1 - 27.77%))
Current Ratio = 0.88 (Total Current Assets 169.5m / Total Current Liabilities 193.7m)
Debt / Equity = 0.62 (Debt 832.1m / totalStockholderEquity, last quarter 1.35b)
Debt / EBITDA = 7.15 (Net Debt 671.3m / EBITDA 93.9m)
Debt / FCF = 2.35 (Net Debt 671.3m / FCF TTM 285.3m)
Total Stockholder Equity = 621.5m (last 4 quarters mean from totalStockholderEquity)
RoA = 5.11% (Net Income 76.2m / Total Assets 2.68b)
RoE = 12.26% (Net Income TTM 76.2m / Total Stockholder Equity 621.5m)
RoCE = 8.08% (EBIT 93.5m / Capital Employed (Equity 621.5m + L.T.Debt 535.7m))
RoIC = 2.64% (NOPAT 67.5m / Invested Capital 2.55b)
WACC = 7.95% (E(1.35b)/V(2.18b) * Re(12.82%) + D(832.1m)/V(2.18b) * Rd(0.09%) * (1-Tc(0.28)))
Discount Rate = 12.82% (= CAPM, Blume Beta Adj.) -> capped to 12.54%
Shares (quarterly) Correlation: 96.24 | Cagr: 12.55%
[DCF] Terminal Value 77.97% ; FCFF base≈172.8m ; Y1≈198.1m ; Y5≈291.5m
[DCF] Fair Price = 9.85 (EV 4.39b - Net Debt 671.3m = Equity 3.72b / Shares 377.2m; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 3.29 | # QB: 1
Revenue Correlation: 49.32 | Revenue CAGR: 58.96% | SUE: 0.75 | # QB: 0
EPS current Quarter (2026-10-31): EPS=-0.01 | Chg30d=N/A | Revisions=+0% | Analysts=1
EPS next Quarter (2027-01-31): EPS=-0.01 | Chg30d=N/A | Revisions=+0% | Analysts=1
EPS current Year (2027-04-30): EPS=0.11 | Chg30d=N/A | Revisions=+25% | GrowthEPS=-73.4% | GrowthRev=-66.2%
EPS next Year (2028-04-30): EPS=0.01 | Chg30d=-66.67% | Revisions=+25% | GrowthEPS=-87.7% | GrowthRev=-34.3%